MedTrace Logo

PD-1 Knockout Engineered T Cells for Metastatic Non-small Cell Lung Cancer

NCT02793856 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2021-01-12

Study results available
· View outcomes & findings →

Summary

This study will evaluate the safety of PD-1 knockout engineered T cells in treating metastatic non-small cell lung cancer. Blood samples will also be collected for research purposes.

Conditions

  • Metastatic Non-small Cell Lung Cancer

Interventions

DRUG

Cyclophosphamide

To deplete Tregs before collecting peripheral blood

OTHER

PD-1 Knockout T Cells

Autologous lymphocytes are collected and PDCD1 gene is knocked out in the laboratory. Cells are selected and expanded ex vivo. Cells are infused back to the patients for treatment

Sponsors & Collaborators

  • Chengdu MedGenCell, Co., Ltd.

    collaborator INDUSTRY

  • Sichuan University

    lead OTHER

Principal Investigators

  • You Lu, MD · Sichuan University

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-08-26
Primary Completion
2018-08-20
Completion
2020-03-17

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02793856 on ClinicalTrials.gov